**Clover Biopharmaceuticals, Ltd.**
**三葉草生物製藥有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 2197)**

# VOLUNTARY ANNOUNCEMENT
# CLOVER'S EFFICACY DATA IN PREVIOUSLY-INFECTED INDIVIDUALS IS PUBLISHED IN LANCET INFECTIOUS DISEASE

This announcement is made by the board (the "**Board**") of directors of Clover Biopharmaceuticals, Ltd. (the "**Company**" or "**Clover**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest clinical development status of the core product of the Group.

The Company is pleased to announce additional data from SPECTRA (Study Evaluating Protective-Efficacy and Safety of the Company's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global pivotal phase 2/3 clinical trial, that shows SCB-2019 (CpG 1018/Alum) provides significant incremental protection against COVID-19 in a previously-infected participant population and has been published in the peer-reviewed journal, *Lancet Infectious Disease*.

This study evaluated the efficacy, safety, and reactogenicity of SCB-2019 (CpG 1018/Alum) in participants who had previously been infected with SARS-CoV-2 before vaccination. Of the 30,174 total participants enrolled in SPECTRA, 14,692 participants with evidence of exposure to SARS-CoV-2 at baseline were evaluated in the full analysis set, with 7,353 individuals randomized in the vaccine arm and 7,339 individuals randomized in the placebo arm.

**Boosting individuals who previously had SARS-CoV-2 infection:** Vaccination with SCB-2019 (CpG 1018/Alum) in individuals previously infected with SARS-CoV-2 showed a cumulative protective effect of 89.7% (95% confidence interval [CI]: 82.5 – 94.4) after one dose and 93.8% (95% CI: 88.9 – 97.0) after two doses against COVID-19 of any severity, against any strain of SARS-CoV-2, as compared to SARS-CoV-2 naive placebo recipients. In the previously-infected population, incremental risk reduction against COVID-19 of any severity of SCB-2019 (CpG 1018/Alum) vaccination versus placebo was 49.9% after one dose and 64.2% after two doses. Further, SCB-2019 (CpG 1018/Alum) demonstrated a favorable safety profile with infrequent severe and serious adverse events (AEs) that were balanced between vaccine and placebo groups. Solicited local AEs were mostly mild and transient cases of pain at the injection site and decreased in frequency after the second dose.

In conclusion, these data highlight that a single-dose or two-dose primary vaccination with SCB-2019 (CpG 1018/Alum) increased protection against COVID-19 following previous exposure to SARS-CoV-2. SCB-2019 (CpG 1018/Alum) remains the first and only COVID-19 vaccine candidate to demonstrate significant protection against COVID-19 of any severity in previously-infected individuals in a randomized clinical efficacy trial, and provides the Company with confidence in advancing the vaccine candidate as a universal COVID-19 booster.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to ultimately commercialize SCB-2019 (CpG 1018/Alum) successfully.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
**Clover Biopharmaceuticals, Ltd.**
**Dr. Peng LIANG**
*Chairman of the Board*

Shanghai, PRC, April 20, 2022

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Mr. Ting XIAO and Mr. Dong LYU as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*